Virus inactivation of plasma intended for transfusion avoids the transmission of hepatitis B virus, hepatitis C virus, and HIV.
However, because most plasma recipients also receive other blood components concomitantly, the procedure reduces but cannot eliminate the risk of transfusion-transmitted infection.
As virus-inactivated plasma has just been licensed in the United States and other countries, a cost-effectiveness analysis is pertinent.
A Monte Carlo simulation of a Markov model representing the possible outcomes of plasma recipients was used to derive costs and utilities of transfusing virus-inactivated plasma instead of standard plasma.
Probability distributions for patients'age and sex and for the number of blood components transfused per case were determined in 924 plasma recipients in a tertiary-care hospital.
Other values were obtained from the medical literature.
Results of the baseline and sensitivity analyses are the mean (± SD) of 10 simulations with 107 patients per simulation.
In the baseline analysis, transfusing virus-inactivated plasma instead of standard plasma prolonged the quality-adjusted survival by 1 hour and 11 minutes per patient, at a cost-effectiveness ratio of $2,156,398 ± $257,587 per quality-adjusted life year gained. (...)
Mots-clés Pascal : Transfusion, Plasma sanguin, Inactivation, Virus, Analyse coût efficacité, Homme, Economie santé
Mots-clés Pascal anglais : Transfusion, Blood plasma, Inactivation, Virus, Cost efficiency analysis, Human, Health economy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0306268
Code Inist : 002B27D01. Création : 16/11/1999.